Pituitary-Ovarian Responses to Nafarelin Testing in the Polycystic Ovary Syndrome

Abstract
To investigate the basis of polycystic ovary syndrome, we examined the responses of patients to nafarelin, a specific gonadotropin-releasing-hormone agonist, given to stimulate pituitary and gonadal secretion. We compared 16 normal women in the follicular phase, 5 normal men, 8 women with polycystic ovary syndrome, and 1 woman with polycystic ovary syndrome caused by a 3β-hydroxysteroid dehydrogenase deficiency.